1
|
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gúrpide J, Burgués O, Hernando C, Bermejo B, Martínez MT, Lluch A, Cejalvo JM, Eroles P. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. Int J Mol Sci 2023; 24:ijms24043601. [PMID: 36835014 PMCID: PMC9966352 DOI: 10.3390/ijms24043601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 02/07/2023] [Accepted: 02/09/2023] [Indexed: 02/16/2023] Open
Abstract
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is evidence that treatment could modulate the tumor microenvironment in a way favoring the propagation of the tumor. In addition, the lymphangiogenesis process and its factors could be involved in this counter-therapeutic event. In our study, we have evaluated the expression of the main lymphangiogenic receptor VEGFR3 in two triple-negative breast cancer in vitro models, resistant or not to doxorubicin treatment. The expression of the receptor, at mRNA and protein levels, was higher in doxorubicin-resistant cells than in parental cells. In addition, we confirmed the upregulation of VEGFR3 levels after a short treatment with doxorubicin. Furthermore, VEGFR3 silencing reduced cell proliferation and migration capacities in both cell lines. Interestingly, high VEGFR3 expression was significantly positively correlated with worse survival in patients treated with chemotherapy. Furthermore, we have found that patients with high expression of VEGFR3 present shorter relapse-free survival than patients with low levels of the receptor. In conclusion, elevated VEGFR3 levels correlate with poor survival in patients and with reduced doxorubicin treatment efficacy in vitro. Our results suggest that the levels of this receptor could be a potential marker of meager doxorubicin response. Consequently, our results suggest that the combination of chemotherapy and VEGFR3 blockage could be a potentially useful therapeutic strategy for the treatment of triple-negative breast cancer.
Collapse
Affiliation(s)
| | - Eduardo Tormo
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
| | | | - Ana Lameirinhas
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
| | - Federico Rojo
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Juan Madoz-Gúrpide
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Octavio Burgués
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Cristina Hernando
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Begoña Bermejo
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - María Teresa Martínez
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Ana Lluch
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
- Department of Medicine, Universidad de Valencia, 46010 Valencia, Spain
| | - Juan Miguel Cejalvo
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Pilar Eroles
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Physiology, Universidad de Valencia, 46010 Valencia, Spain
- Department of Biotechnology, Universidad Politécnica de Valencia, 46022 Valencia, Spain
- Correspondence:
| |
Collapse
|
2
|
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Sci Adv 2022; 8:eabk2746. [PMID: 35594351 PMCID: PMC9122332 DOI: 10.1126/sciadv.abk2746] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Accepted: 04/05/2022] [Indexed: 06/15/2023]
Abstract
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer.
Collapse
Affiliation(s)
| | - Enrique J. Arenas
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
| | - Alex Martínez-Sabadell
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | - Fara Brasó-Maristany
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona 08036, Spain
- Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona 08036, Spain
| | | | - Eduardo Tormo
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
| | - Cristina Hernando
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - María Teresa Martínez
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | | | - Soraya Simón
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - Jesús Poveda
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - Santiago Moragón
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - Sandra Zazo
- Department of Pathology, IIS Fundación Jiménez Díaz, Madrid 28040, Spain
| | - Débora Martínez
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona 08036, Spain
- Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona 08036, Spain
| | - Ana Rovira
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Medical Oncology, Hospital del Mar, Barcelona 08003, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain
| | - Octavio Burgués
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Pathology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - Federico Rojo
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Pathology, IIS Fundación Jiménez Díaz, Madrid 28040, Spain
| | - Joan Albanell
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Medical Oncology, Hospital del Mar, Barcelona 08003, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain
- Pompeu Fabra University (UPF), Barcelona 08002, Spain
| | - Begoña Bermejo
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| | - Ana Lluch
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
- Department of Medicine, Universidad de Valencia, Valencia 46010, Spain
| | - Aleix Prat
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona 08036, Spain
- Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona 08036, Spain
- SOLTI Breast Cancer Research Group, Barcelona 08008, Spain
| | - Joaquín Arribas
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain
- Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Barcelona 08193, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
| | - Pilar Eroles
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Physiology, Universidad de Valencia, Valencia 46010, Spain
| | - Juan Miguel Cejalvo
- INCLIVA Biomedical Research Institute, Valencia 46010, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de València, Valencia 46010, Spain
| |
Collapse
|
3
|
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 2021; 41:77-105. [PMID: 34524579 PMCID: PMC8924146 DOI: 10.1007/s10555-021-09992-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Accepted: 09/02/2021] [Indexed: 12/31/2022]
Abstract
Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain higher than desirable. Alterations in microRNAs have been linked to changes in critical processes related to cancer development and progression. Their involvement in resistance or sensitivity to breast cancer treatments has been documented by different in vivo and in vitro experiments. The most significant microRNAs implicated in modulating resistance to breast cancer therapies are summarized in this review. Resistance to therapy has been linked to cellular processes such as cell cycle, apoptosis, epithelial-to-mesenchymal transition, stemness phenotype, or receptor signaling pathways, and the role of microRNAs in their regulation has already been described. The modulation of specific microRNAs may modify treatment response and improve survival rates and cancer patients' quality of life. As a result, a greater understanding of microRNAs, their targets, and the signaling pathways through which they act is needed. This information could be useful to design new therapeutic strategies, to reduce resistance to the available treatments, and to open the door to possible new clinical approaches.
Collapse
Affiliation(s)
| | | | | | - Ana Lameirinhas
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain
| | | | - Eduardo Tormo
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain.,Center for Biomedical Network Research On Cancer, CIBERONC-ISCIII, 28029, Madrid, Spain
| | | | - Pilar Eroles
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain. .,Center for Biomedical Network Research On Cancer, CIBERONC-ISCIII, 28029, Madrid, Spain. .,Department of Physiology, University of Valencia, 46010, Valencia, Spain.
| |
Collapse
|
4
|
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Pattanayak B, Tormo E, Miranda-Gonçalves VM, Macedo-Silva C, Rojo F, Zazo S, Madoz-Gúrpide J, Burgues O, Hernando C, Martínez M, Moragón S, Bermejo De Las Heras B, Lluch A, Jerónimo C, Eroles P, Cejalvo JM. miR-503-5p induces doxorubicin resistance in triple-negative breast cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.1083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1083 Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer (BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies continue to be the mainstay for treatment of this BC, which lacks targetable markers. In this context, microRNAs have been described to have an important role. The aim of this work was to elucidate the function of miR-503-5p in doxorubicin resistance in TNBC. Methods: miR-503-5p expression was evaluated in the TNBC cell line with acquired resistance to doxorubicin (MDA-MB-231R) and its parental cell line (MDA-MB-231), by qRT-PCR. Studies of gain/loss of function of miR-503-5p were carried out in MDA-MB-231 and MDA-MB-231R cells by transient transfection of mimics and inhibitors. Cells were treated with doxorubicin, and viability was measured by flow cytometry and MTT assay. The role of miR-503-5p was also evaluated in vivo by Chicken Chorioallantoic Membrane (CAM) assay. MDA-MB-231 cells transfected with miR-503-5p mimic or scramble miRNA were inoculated onto the CAM of fertilized chicken eggs. After 48 hours, tumours were treated with doxorubicin or supplemented media for 48 hours and tumour growth was measured. miR-503-5p expression was quantified by qRT-PCR in a retrospective cohort of 74 TNBC patients treated with anthracycline + taxane regimens. Overall survival analysis for miR-503-5p in TNBC patients from METABRIC dataset was evaluated by the KM plotter online tool. Results: miR-503-5p was significantly upregulated in the resistant MDA-MB-231R TNBC cell line when compared to its parental cell line MDA-MB-231 (̃3.5-fold; p< 0.0001). Then, gain/loss function assays showed that upregulation of miR-503-5p in MDA-MB-231 cells increased resistance to doxorubicin ( p< 0.0001) and its downregulation in MDA-MB-231R cells had the opposite effect ( p< 0.0001). Moreover, the role of miR-503-5p was also confirmed in the CAM assay in vivo model, where miR-503-5p overexpression inhibited the effect of doxorubicin. In our cohort of patients, miR-503-5p expression levels in core biopsies sampled before preoperative chemotherapy were associated with residual cancer burden (RCB). miR-503-5p expression was significantly higher in patients with poor response to chemotherapy (RCB II and III; median, 95% CI: 0.00055, 0.00024 - 0.00136) than in patients with good response (RCB 0 and I; median, 95% CI: 0.00018, 0.00011 - 0.00034; p = 0.036). Moreover, we confirmed that TNBC patients with high expression of miR-503-5p had worse overall survival than patients with low expression ( p= 0.016). Conclusions: We identified miR-503-5p as a modulator of doxorubicin resistance in TNBC. Our in vitro findings are supported by the clinical data of TNBC patients and in vivo assays. Hence, the inhibition of miR-503-5p may be a promising strategy to improve chemotherapeutic efficacy. Moreover, the expression levels of miR-503-5p may be used as a biomarker for therapy response in TNBC.
Collapse
Affiliation(s)
| | | | | | | | - Eduardo Tormo
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Vera Mónica Miranda-Gonçalves
- Cancer Biology and Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal
| | - Catarina Macedo-Silva
- Cancer Biology and Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal
| | - Federico Rojo
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Sandra Zazo
- Translational Oncology Division, Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | | | - Octavio Burgues
- Department of Pathology. Hospital Clinico Universitario de Valencia, Valencia, Spain
| | - Cristina Hernando
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain
| | - Maite Martínez
- Hospital Clinico Universitario de Valencia, Incliva, Valencia, Spain
| | - Santi Moragón
- Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - Begoña Bermejo De Las Heras
- Hospital Clinico Universitario de Valencia, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Carmen Jerónimo
- Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
| | - Pilar Eroles
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Juan Miguel Cejalvo
- Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain
| |
Collapse
|
5
|
Adam-Artigues A, Carbonell-Asíns JA, Zúñiga-Trejos S, Moragón S, Martínez MT, Hernando C, Tormo E, Burgués O, Lluch A, Bermejo B, Eroles P, Cejalvo JM. Abstract PS19-20: Identification of a novel two-microRNA signature for recurrence prediction in HER2 positive breast cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps19-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2+ breast cancer (BC) is a heterogeneous disease. Despite the novel targeted therapies against HER2, 20% of patients relapse. In this context, the identification of prognostic and predictor biomarkers is needed.MicroRNAs are involved in BC development and prognosis. We aim at assessing the prognostic significance of two micro-RNAs (named as A and B) in HER2+ BC tissue, to propose signature to predict relapse in this setting of patients.Methods: This study was conducted in a cohort of 46 non-consecutive HER2+ BC patients diagnosed at Hospital Clínico València-INCLIVA. All BC patients received standard treatment for localized disease. RNA was isolated from formalin-fixed paraffin-embedded primary tumor and retro-transcribed to cDNA. MicroRNA expression levels were measured by real-time qPCR and results were normalized according to the expression of housekeeping mir-16 miRNA.Non-parametric Mann-Whitney U test was used to ascertain the statistical significance of differences in miRNA expression levels between disease-free and relapse. Receiver operator characteristics (ROC) curves were constructed and AUC, accuracy, specificity and sensitivity, were calculated as a biomarker performance parameter. The best cutoff value was established based on the highest value obtained in ROC curve analysis according to the maximization of the sum of sensitivity and specificity. Kaplan-Meier curves were plotted for disease-free survival (DFS) based on the best cutoff value. As both microRNA showed high correlation (r=0.85), a genetic signature was developed using Principal Component Analysis (PCA) and extracting the first component. MicroRNA targeted genes were downloaded from miRTarBase (release 7.0). Cytoscape (v3.8.0) and ClueGo (v2.5.6) and were used to perform functional enrichment analysis with the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. To select significant terms/pathways, p-values were adjusted by the Benjamni-Hochberg method (p<0.05). Results: The expression of both microRNA-A and B was higher in the primary tumor of those patients who relapsed after treatment compared to those free of disease (p= 0.003 and 0.0002, respectively). ROC curves demonstrated that microRNA-A and B might discriminate those HER2+ BC patients who relapse. MicroRNA-A predicts relapse with an AUC 0.740, sensitivity of 0.810, specificity of 0.583 and accuracy of 0.689, and microRNA-B presented an AUC 0.821, sensitivity of 0.810, specificity of 0.750, and accuracy of 0.778. The survival analysis showed that microRNA-A and B strongly predicted shorter DFS (p= 0.014 and 0.0012, respectively).Two-microRNA signature combining (PCA1= 99.4% absorbed variance) microRNA-A and microRNA-B expression levels had high performance in discriminating relapsed from non-relapsed HER2+ BC patients (AUC 0.748, accuracy 0.689, sensitivity 1, specificity 0.417). Signature predicted DFS (p= 0.009). Functional enrichment analysis returned 55 significant pathways. Of these, important pathways related to tumorigenesis and response to treatment were enriched. Interestingly, P53 pathway, apoptosis, and cell cycle were in the top 5 enriched pathways. Conclusions: We demonstrated the value of microRNA A and B as potential prognostic biomarkers. High expression was related to poor prognosis in over cohort of HER2+ BC patients. Both microRNAs were able to strongly discriminate patients who will relapse and predict shorter DFS. Moreover, our signature was able to predict the outcome, suggesting a potential prognostic role at diagnosis. Both microRNAs are related to important biological pathways associated to BC progression. Further investigations to optimize the micro-RNA signature are on-going.
Citation Format: Anna Adam-Artigues, Juan Antonio Carbonell-Asíns, Sheila Zúñiga-Trejos, Santiago Moragón, Maria Teresa Martínez, Cristina Hernando, Eduardo Tormo, Octavio Burgués, Ana Lluch, Begoña Bermejo, Pilar Eroles, Juan Miguel Cejalvo. Identification of a novel two-microRNA signature for recurrence prediction in HER2 positive breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS19-20.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Eduardo Tormo
- 1INCLIVA Biomedical Research Institute, Valencia, Spain
| | | | - Ana Lluch
- 1INCLIVA Biomedical Research Institute, Valencia, Spain
| | | | - Pilar Eroles
- 1INCLIVA Biomedical Research Institute, Valencia, Spain
| | | |
Collapse
|
6
|
Oltra SS, Peña-Chilet M, Martinez MT, Tormo E, Cejalvo JM, Climent J, Eroles P, Lluch A, Ribas G. miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker. Breast Cancer (Auckl) 2020; 14:1178223420977845. [PMID: 33311984 PMCID: PMC7716059 DOI: 10.1177/1178223420977845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 11/06/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE The study of breast cancer nearly always involves patients close to menopause or older. Therefore, young patients are mostly underrepresented. Our aim in this study was to demonstrate biological differences in breast cancer of young people using as a model available cell lines derived from people with breast cancer younger than 35 years. METHODS Global miRNA expression was analyzed in breast cancer cells from young (HCC1500, HCC1937) and old patients (MCF-7, MDA-MB-231, HCC1806, and MDA-MB-468). In addition, it was compared with same type of results from patients. RESULTS We observed a differential profile for 155 miRNAs between young and older cell lines. We identified a set of 24 miRNA associated with aggressiveness that were regulating pluripotency of stem cell-related pathways. Combining the miRNA expression data from cell lines and breast cancer patients, 132 miRNAs were differently expressed between young and old samples, most of them previously found in cell lines. MiR-23a-downregulation was also associated with poor survival in young patients. CONCLUSIONS Our results suggest that HCC1500 and HCC1937 cell lines could be suitable cellular models for breast cancer affecting young women. The miR-23a-downregulation could have a potential role as a poor prognosis biomarker in this age group.
Collapse
Affiliation(s)
- Sara S Oltra
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Maria Peña-Chilet
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Maria T Martinez
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Eduardo Tormo
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Juan Miguel Cejalvo
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Joan Climent
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Pilar Eroles
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Ana Lluch
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Gloria Ribas
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| |
Collapse
|
7
|
Pattanayak B, Garrido-Cano I, Adam-Artigues A, Tormo E, Pineda B, Cabello P, Alonso E, Bermejo B, Hernando C, Martínez MT, Rovira A, Albanell J, Rojo F, Burgués O, Cejalvo JM, Lluch A, Eroles P. MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma. Front Oncol 2020; 10:1661. [PMID: 33014831 PMCID: PMC7511588 DOI: 10.3389/fonc.2020.01661] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Accepted: 07/28/2020] [Indexed: 12/11/2022] Open
Abstract
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients’ samples. The upregulation of miR-33b suppressed proliferation, induced apoptosis, reduced invasion, migration and regulated EMT by an increase of E-cadherin and a decrease of ß-catenin and vimentin. The silencing of EZH2 mimicked the impact of miR-33b overexpression. Furthermore, the inhibition of miR-33b induces cell proliferation, invasion, migration, EMT, and EZH2 expression in non-tumorigenic cells. Importantly, the Kaplan–Meier analysis showed a significant association between high miR-33b expression and better overall survival. These results suggest miR-33b as a suppressive miRNA that could inhibit tumor metastasis and invasion in HER2+ BC partly by impeding EMT through the repression of the MYC–EZH2 loop.
Collapse
Affiliation(s)
| | | | | | - Eduardo Tormo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain
| | - Begoña Pineda
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Physiology, University of Valencia, Valencia, Spain
| | - Paula Cabello
- Biomedical Research Institute, INCLIVA, Valencia, Spain
| | - Elisa Alonso
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Hospital Clinico de Valencia, Valencia, Spain
| | - Begoña Bermejo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Cristina Hernando
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - María Teresa Martínez
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Ana Rovira
- Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain.,Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Federico Rojo
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain
| | - Octavio Burgués
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Hospital Clinico de Valencia, Valencia, Spain
| | - Juan Miguel Cejalvo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Ana Lluch
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Physiology, University of Valencia, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Pilar Eroles
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,COST action CA15204, Brussels, Belgium
| |
Collapse
|
8
|
Aguado EO, Martinez M, Carbonell-Asins J, Montón-Bueno J, Ortega B, Poveda J, Tapia M, Moragón S, Melia CH, Candia L, Simon S, Adam-Artigues A, Garrido-Cano I, Pattanayak B, Tormo E, Eroles P, Lluch A, De Las Heras BB, Cejalvo J. 319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
9
|
Adam-Artigues A, Tormo E, Cervera R, Rojo F, Pérez-Fidalgo A, Zazo S, González-Alonso P, Hernándo C, Martínez MT, Gambardella V, Poveda J, Simón S, Ortega B, Moragón S, Rovira A, Albanell J, Burgués O, Bermejo B, Eroles P, Lluch A, Cejalvo JM. Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-03-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) is a heterogeneous disease. HER2+ BC represents between 15-20% of cases. Trastuzumab, a monoclonal antibody, has been successfully improved clinical benefits in both localized and advanced setting. Despite this evidence, many patients experience resistance to therapy. The objective of this study is to analyze AXL receptor as a potential mechanism of resistance and its implication as a prognostic factor. Methods: We used three breast cancer cell lines with acquired resistance to Trastuzumab. Resistant models were generated by treating parental cells (AU565, SKR3, BT474) with constant dose of Trastuzumab (15μg/mL) for 6 months. Cell viability was estimated by MTT assay. Proteins were assessed by Western blot and genes by qRT-PCR. AXL was downregulated by siRNA and a selective tyrosine kinase (TK) AXL inhibitor (TP-0903). Proteins interaction was assessed by immunoprecipitation and Duolink®PLA. The prognostic value of AXL was evaluated in primary tumor in a cohort of HER2+ BC patients treated with Trastuzumab plus chemotherapy from our center (n=33). Results: Acquired resistant cell lines (RCLs) maintained HER2 amplification. RCLs were more proliferative than sensitive parental cell lines. There was an important up-regulation of AXL (>2.5 fold-change) and epithelial-mesenchymal transition markers (VIM, CDH2, CTNNB1 and FN1) in RCLs (p<0.05). Sensitivity to Trastuzumab was restored by silencing AXL and by using TP-0903 both able to cause a decrease in cell viability and Trastuzumab IC50 (p<0.05). AXL high expression was ligand independent, as GAS6 was not increased. Heterodimerization between AXL and HER2 was observed among our RCLs. In our cohort, AXL high expression was detected in patients who relapsed and it was associated with worse prognosis with a decrease of disease-free survival (p<0.05). The worse prognostic role of AXL was validated in a public data set (p<0.001). Conclusions: Our results suggest: 1) RCLs were more proliferative and showed mesenchymal-like enriched phenotype; 2) AXL-HER2 dimer was identified as a potential mechanism of secondary resistance to Trastuzumab; 3) genetic and pharmacological AXL inhibition restored sensitivity to Trastuzumab in in vitro models; 4) AXL expression was associated with worse prognosis in our HER2+ trastuzumab-treated BC patients and validated in silico. These results showed AXL as a prognostic factor and a potential therapeutic target in HER2+ patients with resistance to Trastuzumab and AXL overexpression.
Citation Format: Anna Adam-Artigues, Eduardo Tormo, Raimundo Cervera, Federico Rojo, Alejandro Pérez-Fidalgo, Sandra Zazo, Paula González-Alonso, Cristina Hernándo, María Teresa Martínez, Valentina Gambardella, Jesús Poveda, Soraya Simón, Belén Ortega, Santiago Moragón, Ana Rovira, Joan Albanell, Octavio Burgués, Begoña Bermejo, Pilar Eroles, Ana Lluch, Juan Miguel Cejalvo. AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-03-05.
Collapse
Affiliation(s)
- Anna Adam-Artigues
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Eduardo Tormo
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Raimundo Cervera
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Federico Rojo
- 2Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | | | - Sandra Zazo
- 2Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | | | - Cristina Hernándo
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | | | | | - Jesús Poveda
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Soraya Simón
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Belén Ortega
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Santiago Moragón
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Ana Rovira
- 3Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Joan Albanell
- 3Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Octavio Burgués
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Begoña Bermejo
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Pilar Eroles
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Ana Lluch
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Juan Miguel Cejalvo
- 1Hospital Clinico Valencia- Biomedical Research Institute INCLIVA, Valencia, Spain
| |
Collapse
|
10
|
Adam-Artigues A, Tormo E, Rojo F, Perez-Fidalgo J, Zazo S, Gonzalez-Alonso P, Hernando C, Martínez M, Gambardella V, Poveda J, Simón S, Moragon S, Alonso E, Albanell J, Burgues O, Bermejo B, Eroles P, Lluch A, Cejalvo J, Rovira A. The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep 2019; 9:5316. [PMID: 30926829 PMCID: PMC6441107 DOI: 10.1038/s41598-019-41472-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Accepted: 03/11/2019] [Indexed: 12/17/2022] Open
Abstract
The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of the miRNA-449 family in the response to doxorubicin. The cell viability, cell-cycle phases, and the expression of in silico target genes and proteins of sensitive/resistant triple negative breast cancer cell lines were evaluated in response to doxorubicin treatment and after gain/loss of miRNAs-449 function achieved by transient transfection. Triple negative breast cancer patients were selected for ex vivo experiments and to evaluate gene and miRNAs expression changes after treatment, as well as survival analysis by Kaplan-Meier. Doxorubicin treatment upregulated miRNAs-449 and DNA-damage responder factors E2F1 and E2F3 in triple negative breast cancer sensitive breast cancer cells, while expression remained unaltered in resistant ones. In vitro overexpression of miRNAs-449 sensitized cells to the treatment and significantly reduced the resistance to doxorubicin. These changes showed also a strong effect on cell cycle regulation. Finally, elevated levels of miRNA-449a associated significantly with better survival in chemotherapy-treated triple negative breast cancer patients. These results reveal for the first time the involvement of the miRNA-449 family in doxorubicin resistance and their predictive and prognostic value in triple negative breast cancer patients.
Collapse
Affiliation(s)
- Eduardo Tormo
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain
| | | | | | - Octavio Burgués
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain.,Pathology Department, Hospital Clínico Universitario, Valencia, Spain
| | - Elisa Alonso
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain.,Pathology Department, Hospital Clínico Universitario, Valencia, Spain
| | - Begoña Bermejo
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain
| | - Silvia Menéndez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
| | - Sandra Zazo
- Pathology Department, IIS- Fundación Jiménez Díaz- CIBERONC, Madrid, Spain
| | - Juan Madoz-Gúrpide
- Pathology Department, IIS- Fundación Jiménez Díaz- CIBERONC, Madrid, Spain
| | - Ana Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.,Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.,Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Federico Rojo
- Pathology Department, IIS- Fundación Jiménez Díaz- CIBERONC, Madrid, Spain
| | - Ana Lluch
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain.,Universidad de Valencia, Valencia, Spain
| | - Pilar Eroles
- INCLIVA Biomedical Research Institute, Valencia, Spain. .,Oncology and Hematology Department, Hospital Clínico Universitario-CIBERONC, Valencia, Spain. .,COST action CA15204, Brussels, Belgium.
| |
Collapse
|
12
|
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Cabello P, Pineda B, Tormo E, Albanell J, Rojo F, Lluch A, Eroles P. Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Pattanayak B, Herrera G, Garrido-Cano I, Adam-Artigues A, Tormo E, Pineda Merlo B, Cabello P, Lluch A, Eroles P. Characterization of the different cell population in primary culture of breast tumor. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy318.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Adam Artigues A, Tormo E, Cerro-Herreros E, Sabater M, Garrido-Cano I, Pineda Merlo B, Pattanayak B, Cabello P, Artero R, Eroles P. Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Cabello P, Forés J, Tormo E, Pineda B, Adam A, Garrido I, Pattanayak B, Lluch A, Eroles P. Involvement of microRNA-146a in trastuzumab resistance of HER2+ breast cancer cells. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx513.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Pattanayak B, Adam-Artigues A, Tormo E, Garrido I, Pineda B, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. Micro-RNA 33b inhibits breast cancer migration and invasion through regulating epithelial-mesenchymal transition in HER2 positive breast cancer cell lines. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx511.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Eroles P, Tormo E, Pineda B, Espin E, Lluch A. MicroRNAs in Breast Cancer: One More Turn in Regulation. Curr Drug Targets 2017; 17:1083-100. [PMID: 25694121 DOI: 10.2174/1389450116666150213114103] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Revised: 12/16/2015] [Accepted: 01/30/2015] [Indexed: 11/22/2022]
Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules that critically regulate the expression of genes. MiRNAs are involved in physiological cellular processes; however, their deregulation has been associated with several pathologies, including cancer. In human breast cancer, differently expressed levels of miRNAs have been identified from those in normal breast tissues. Moreover, several miRNAs have been correlated with pathological phenotype, cancer subtype and therapy response in breast cancer. The resistance to therapy is increasingly a problem in patient management, and miRNAs are emerging as novel therapeutic targets and potential predictive biomarkers for treatment. This review provides an overview of the current situation of miRNAs in breast cancer, focusing on their involvement in resistance and the circulating miRNA. The mechanisms of therapeutic resistance regulated by miRNAs, such as the regulation of receptors, the modification of enzymes of drug metabolism, the inhibition of cell cycle control or pro-apoptotic proteins, the alteration of histone activity and the regulation of DNA repair machinery among others, are discussed for breast cancer clinical subtypes. Additionally, in this review, we summarize the recent knowledge that has established miRNA detection in peripheral body fluids as a suitable biomarker. We review the detection of miRNA in liquid biopsies and its implications for the diagnosis and monitoring of breast cancer. This new generation of cancer biomarkers may lead to a significant improvement in patient management.
Collapse
|
18
|
Cejalvo J, Tormo E, Adam A, Rojo F, Pineda B, Zazo S, Gonzalez-Alonso P, Sabbaghi M, Alonso E, Rovira A, Albanell J, Bermejo De Las Heras B, Burgues O, Lluch A, Perez Fidalgo J, Eroles P. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, González-Alonso P, Albanell J, Rovira A, Rojo F, Lluch A, Eroles P. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep 2017; 7:41309. [PMID: 28120942 PMCID: PMC5264595 DOI: 10.1038/srep41309] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 12/19/2016] [Indexed: 01/05/2023] Open
Abstract
A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated in trastuzumab treated HER2+ BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate resistance), and MDA-MB-231 (HER2−) cell lines, and the expression of miR-26a, miR-30b, and their target genes was measured. BT474 wt cell viability decreased by 60% and miR-26a and miR-30b were significantly overexpressed (~3-fold, p = 0.003 and p = 0.002, respectively) after trastuzumab treatment, but no differences were observed in resistant and control cell lines. Overexpression of miR-30b sensitized BT474r cells to trastuzumab (p = 0.01) and CCNE2, was significantly overexpressed after trastuzumab treatment in BT474r cells (p = 0.032), but no significant changes were observed in sensitive cell line. When CCNE2 was silenced BT474r cell sensitivity to trastuzumab increased (p = 0.03). Thus, the molecular mechanism of trastuzumab action in BT474 cell line may be regulated by miR-26a and miR-30b and CCNE2 overexpression might play an important role in acquired trastuzumab resistance in HER2+ breast cancer given that resistance was diminished when CCNE2 was silenced.
Collapse
Affiliation(s)
- Eduardo Tormo
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
| | | | | | - Begoña Pineda
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
| | - Sandra Zazo
- Pathology Department, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain
| | | | - Joan Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain.,Medical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain.,Pompeu Fabra University, 08002 Barcelona, Spain
| | - Ana Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain.,Medical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain
| | - Federico Rojo
- Pathology Department, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Ana Lluch
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.,Oncology and Hematology Department, Hospital Clínico Universitario, 46010 Valencia, Spain
| | - Pilar Eroles
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
| |
Collapse
|
20
|
Cabello P, Pineda B, Tormo E, Lluch A, Eroles P. The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. Int J Mol Sci 2016; 17:E1298. [PMID: 27517917 PMCID: PMC5000695 DOI: 10.3390/ijms17081298] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 07/29/2016] [Accepted: 08/04/2016] [Indexed: 12/22/2022] Open
Abstract
Metformin, a drug approved for diabetes type II treatment, has been associated with a reduction in the incidence of breast cancer and metastasis and increased survival in diabetic breast cancer patients. High levels of miR-26a expression have been proposed as one of the possible mechanisms for this effect; likewise, this miRNA has also been associated with survival/apoptosis processes in breast cancer. Our aim was to evaluate if miR-26a and some of its targets could mediate the effect of metformin in breast cancer. The viability of MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cell lines was evaluated with an MTT assay after ectopic overexpression and/or downregulation of miR-26a. Similarly, the expression levels of the miR-26a targets CASP3, CCNE2, ABL2, APAF1, XIAP, BCL-2, PTEN, p53, E2F3, CDC25A, BCL2L1, MCL-1, EZH2, and MTDH were assessed by quantitative polymerase chain reaction (PCR). The effect of metformin treatment on breast cancer cell viability and miR-26a, BCL-2, PTEN, MCL-1, EZH2, and MTDH modulation were evaluated. Wound healing experiments were performed to analyze the effect of miR-26a and metformin treatment on cell migration. MiR-26a overexpression resulted in a reduction in cell viability that was partially recovered by inhibiting it. E2F3, MCL-1, EZH2, MTDH, and PTEN were downregulated by miR-26a and the PTEN (phosphatase and tensin homolog) protein was also reduced after miR-26a overexpression. Metformin treatment reduced breast cancer cell viability, increased miR-26a expression, and led to a reduction in BCL-2, EZH2, and PTEN expression. miR-26a inhibition partly prevents the metformin viability effect and the PTEN and EZH2 expression reduction. Our results indicate that metformin effectively reduces breast cancer cell viability and suggests that the effects of the drug are mediated by an increase in miR-26a expression and a reduction of its targets, PTEN and EHZ2 Thus, the use of metformin in breast cancer treatment constitutes a promising potential breast cancer therapy.
Collapse
Affiliation(s)
- Paula Cabello
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
| | - Begoña Pineda
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
| | - Eduardo Tormo
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
| | - Ana Lluch
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
- Oncology and Hematology Department, Hospital Clinico Universitario, 46010 Valencia, Spain.
| | - Pilar Eroles
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
| |
Collapse
|
21
|
Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, Chirivella E, Climent J, Lluch A, Eroles P. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer. J Cell Biochem 2016; 116:2061-73. [PMID: 25802200 DOI: 10.1002/jcb.25162] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 03/10/2015] [Indexed: 12/16/2022]
Abstract
UNLABELLED Chemotherapy treatment is the standard in triple negative breast cancers, a cancer subgroup which lacks a specific target. The mechanisms leading to the response, as well as any markers that allow the differentiation between responder and non-responder groups prior to treatment are unknown. In parallel, miRNAs can act as oncogenes or tumor suppressors and there is evidence of their involvement in promoting resistance to anticancer drugs. Therefore we hypothesized that changes in miRNA expression after doxorubicin treatment may also be relevant in treatment response. OBJECTIVE To study miRNAs that are differentially expressed in response to doxorubicin treatment. METHODS One luminal-A and two triple negative, breast cancer cell lines were exposed to doxorubicin. Microarray analysis was performed to identify the common and differentially modified miRNAs. Genes and pathways that are theoretically regulated by these miRNAs were analyzed. RESULTS Thirteen miRNAs common to all three lines were modified, in addition to 25 that were specific to triple negative cell lines, and 69 that changed only in the luminal-A cell line. This altered expression pattern seemed to be more strongly related to the breast cancer subgroup than to the treatment. The analysis of target genes revealed that cancer related pathways were the most affected by these miRNAs, moreover many of them had been previously related to chemotherapy resistance; thus suggesting follow-up studies. Additionally, through functional assays, we showed that miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability, suggesting a role for this miRNA in resistance.
Collapse
Affiliation(s)
- Eduardo Tormo
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Begoña Pineda
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Eva Serna
- Unidad Central de, Investigación en Medicina-INCLIVA, Universitat de Valencia, Valencia, Spain
| | - Alba Guijarro
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Gloria Ribas
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Jaume Fores
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | | | - Joan Climent
- INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Ana Lluch
- INCLIVA Biomedical Research Institute, Valencia, Spain.,Department of Hematology and Medical Oncology, Hospital Clínico Universitario de, Valencia, Spain
| | - Pilar Eroles
- INCLIVA Biomedical Research Institute, Valencia, Spain
| |
Collapse
|
22
|
Perez-Fidalgo J, Espin E, Tormo E, Pineda B, Cejalvo J, Sabbaghi M, Alonso E, Rovira A, Rojo F, Albanell J, Bermejo B, Burgues O, Lluch A. 160 AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30057-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC. BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leuk Res 2015; 39:S0145-2126(15)30367-2. [PMID: 26344465 DOI: 10.1016/j.leukres.2015.08.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 08/14/2015] [Accepted: 08/25/2015] [Indexed: 11/24/2022]
Abstract
Recent data suggest that constitutional genetic variation in the antiapoptotic BCL2 gene could be associated with the susceptibility to develop chronic myeloid leukemia (CML) and the clinical outcome in several hematological malignancies. The present study examines whether BCL2 single nucleotide polymorphisms (SNPs) predispose to CML or may potentially influence the disease characteristics at diagnosis. Notably, no association was observed between the four candidate BCL2 SNPs and the risk of developing CML. Instead, the 4777C>A (rs2279115) and the 5735A>G (rs1801018) SNPs were significantly associated with the disease risk profile as determined by the Sokal score. We found that such polymorphisms correlated with the expression of BCL2 alternative splicing transcripts (BCL2-α, BCL2-β) in healthy donors, but not in CML patients, although the relative levels of BCL2 mRNA splicing variants were shown to change during the clinical course of CML. Our findings suggest that BCL2 polymorphisms could influence the clinical features of CML patients at diagnosis. However, the pathogenic mechanisms involved in such association remain to be ascertained.
Collapse
Affiliation(s)
- Vicent Guillem
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Paula Amat
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - María Collado
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
| | | | | | | | - Eduardo Tormo
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Pilar Eroles
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Carlos Solano
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
| | - Juan Carlos Hernández-Boluda
- Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
| |
Collapse
|
24
|
Espin E, Perez-Fidalgo JA, Tormo E, Pineda B, Cejalvo JM, Sabbaghi M, Alonso E, Rovira A, Rojo F, Albanell J, Bermejo B, Burgues O, Eroles P, Lluch A. Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+ breast cancer cells with de novo resistance to trastuzumab. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e11592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Eduardo Tormo
- Institute of Health Research (INCLIVA), Valencia, Spain
| | | | | | - MohammadA Sabbaghi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Elisa Alonso
- Phatology Deparment, Hospital Clinico Valencia, Valencia, Spain
| | - Ana Rovira
- Hospital del Mar, IMIM, Barcelona, Spain
| | - Federico Rojo
- Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Joan Albanell
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | | | - Octavio Burgues
- Phatology Deparment, Hospital Clinico Valencia, Valencia, Spain
| | - Pilar Eroles
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia, Valencia, Spain
| |
Collapse
|
25
|
Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G. MicroRNA profile in very young women with breast cancer. BMC Cancer 2014; 14:529. [PMID: 25047087 PMCID: PMC4223555 DOI: 10.1186/1471-2407-14-529] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Accepted: 07/15/2014] [Indexed: 12/20/2022] Open
Abstract
Background Breast cancer is rarely diagnosed in very young women (35years old or younger), and it often presents with distinct clinical-pathological features related to a more aggressive phenotype and worse prognosis when diagnosed at this early age. A pending question is whether breast cancer in very young women arises from the deregulation of different underlying mechanisms, something that will make this disease an entity differentiated from breast cancer diagnosed in older patients. Methods We performed a comprehensive study of miRNA expression using miRNA Affymetrix2.0 array on paraffin-embedded tumour tissue of 42 breast cancer patients 35 years old or younger, 17 patients between 45 and 65 years old and 29 older than 65 years. Data were statistically analyzed by t-test and a hierarchical clustering via average linkage method was conducted. Results were validated by qRT-PCR. Putative targeted pathways were obtained using DIANA miRPath online software. Results The results show a differential and unique miRNA expression profile of 121 miRNAs (p-value <0.05), 96 of those with a FDR-value <0.05. Hierarchical clustering grouped the samples according to their age, but not by subtype nor by tumour characteristics. We were able to validate by qRT-PCR differences in the expression of 6 miRNAs: miR-1228*, miR-3196, miR-1275, miR-92b, miR-139 and miR-1207. Moreover, all of the miRNAs maintained the expression trend. The validated miRNAs pointed out pathways related to cell motility, invasion and proliferation. Conclusions The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Gloria Ribas
- Medical Oncology and Hematology Unit, INCLIVA Biomedical Research Institute, Av, Blasco Ibañez, 17, Valencia 46010, Spain.
| |
Collapse
|
26
|
Tormo E, Pineda B, Ballester S, Burgues O, Serna E, Lluch A, Eroles P. Thirteen miRNAs involved in the response of breast cancer cells to doxorubicin. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e12019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12019 Background: Mature microRNAs (miRNAs) are a class of naturally occurring, small non-coding RNA molecules, about 21–25 nucleotides. Growing evidence shows that miRNAs exhibit a variety of regulatory functions related to cell growth, development, and differentiation, and are associated with a wide variety of human diseases. Several miRNAs have been linked to cancer; since expression analysis studies have revealed perturbed miRNA expression in tumors compared to normal tissues. As a consequence, human miRNAs are likely to be highly useful as biomarkers, especially for future cancer diagnostics, and are emerging as targets for disease intervention. Since doxorubicin (DOX) has been used for a long time in breast cancer treatment, and resistance mechanisms are not clear understood, the aim of this work was to find a miRNA expression profile that could explain the regulation in different breast cancer cell lines under DOX treatment. Methods: Three breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF-7) were cultured in normal conditions and also treated with DOX. Total RNA containing small non-coding RNA was isolated and its expression profile was performed by using GeneChip miRNA 2.0 array. Real time PCR validation was carried out to confirm the results. Results: Principal Component Analysis (PCA) of the small non-coding RNA profiles showed different expression patterns between normal conditions and DOX treatment in each cell line separately. Taken together in a Heat Map, miRNA expression profiles of MDA-MB-231 and MDA-MB-468 cell lines were closer in both normal and DOX treatment conditions, while miRNA expression profile of MCF-7 cell line showed strong differences. Total of 13 common miRNAs between the three cell lines were found to be significantly affected by DOX treatment. PCR validation confirmed the results obtained. Conclusions: We conclude that 13 common miRNAs are responsables of changes compared to treatment with DOX in breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF-7. This miRNAs are mainly related with cellular processes such as cell differentiation, vascularisation, apoptosis and cell proliferation and also involved in other cellular processes, such as cell migration.
Collapse
Affiliation(s)
- Eduardo Tormo
- Institute of Health Research (INCLIVA), Valencia, Spain
| | | | | | - Octavio Burgues
- Department of Pathology. Hospital Clinico Universitario de Valencia, Valencia, Spain
| | - Eva Serna
- Central Unit Research on Medicine (INCLIVA), Valencia, Spain
| | - Ana Lluch
- Hospital Clínico de Valencia - INCLIVA Health Research Institute, University of Valencia., Valencia, Spain
| | - Pilar Eroles
- Institute of Health Research (INCLIVA), Valencia, Spain
| |
Collapse
|
27
|
Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Epistatic interaction of Arg72Pro TP53 and −710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival. Mol Cell Biochem 2013; 379:181-90. [DOI: 10.1007/s11010-013-1640-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Accepted: 03/28/2013] [Indexed: 01/30/2023]
|
28
|
Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat 2012; 133:769-78. [PMID: 22315135 DOI: 10.1007/s10549-012-1980-1] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Accepted: 01/24/2012] [Indexed: 01/08/2023]
Abstract
Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development and progression of solid tumours. The association between polymorphisms of angiogenesis pathway genes and risk of breast cancer (BC) has been widely studied, but the results are not conclusive. This information is especially limited in Spanish women, so we decided to conduct a case-control study. Here, we selected four commonly studied polymorphisms in VEGF, rs3025039 (known as +936 C/T), rs1109324, rs154765 and rs833052, one polymorphism at the promoter of the VEGFR1 (-710 C/T) and another in the FGF2, rs1449683, gene to explore their association with BC susceptibility. Genotyping was performed by TaqMan SNP assays and polymerase chain reaction-restriction fragment length polymorphis (PCR-RFLP) on 453 patients and 461 controls in a population from Valencia (Spain). We observed that women carriers of +936 CT + TT VEGF genotypes have a protective effect concerning this disease (p = 0.014; OR 0.67, 95% CI 0.48-0.92) in the global group of patients. The haplotype TGAC of VEGF (rs3025039, rs1109324, rs154764 and rs833052) shows a reduction of the risk to develop BC (p = 3e-04; OR 0.48, 95% CI 0.32-0.72). Furthermore, we found that carriers of -710 CT + TT VEGFR1 genotypes have also a protective effect (p = 0.039; OR 0.55, 95% CI 0.31-0.98). When we stratified by groups of ages these associations were maintained. Our data report for the first time the association of the polymorphism -710 C/T VEGFR1 with BC. Additional experiments focused on VEGF-A, VEGFR1 and sVEGFR1 gene expression demonstrated that carriers of T allele at -710 C/T VEGFR1 genotype have higher levels of sVEGFR1/VEGF-A than the C/C genotype carriers. This was consistent with the hypothesis that this polymorphism may act as low penetrance risk factor. The data provided suggest that +936 C/T VEGF and -710 C/T VEGFR1 genotypes are likely important genetic markers of susceptibility to BC.
Collapse
Affiliation(s)
- Patricia Rodrigues
- Fundación Investigación Hospital Clínico Universitario/INCLIVA, Valencia, Spain.
| | | | | | | | | | | |
Collapse
|
29
|
Falcó C, Tormo G, Estellés A, España F, Tormo E, Gilabert J, Velasco JA, Aznar J. Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica 2001; 86:92-8. [PMID: 11146577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES The incidence of coronary artery disease (CAD) is higher in post-menopausal than in pre-menopausal women. Epidemiological studies suggest that hormone replacement therapy (HRT) decreases the risk of cardiovascular disease in post-menopausal women. HRT could modify the cardiovascular risk via several mechanisms, including modifications in the fibrinolytic system and lipoprotein (a) levels. Our study was aimed at investigating some of these modifications. DESIGN AND METHODS In the cross-sectional part of the study we evaluated several components of the fibrinolytic system, coagulation inhibitors and lipid profile in premenopausal (n=15) and post-menopausal women (n=64) with CAD and compared these parameters with those of healthy pre-menopausal (n=31) and post-menopausal women (n=88). The prospective part of the study analyzed the effect of HRT with transdermal estrogen with or without progestogen in post-menopausal women with CAD. RESULTS Pre- and postmenopausal women with CAD showed significant lower fibrinolytic activity and higher plasminogen activator inhibitor type 1 (PAI-1) levels than their control groups. Lp(a) levels were higher in premenopausal women with CAD than in healthy premenopausal women. In post-menopausal women with CAD, HRT induced a significant decrease in PAI-1 and Lp(a) levels. No significant differences were observed in any parameter studied between the groups treated with transdermal estrogen with and without progestogen. INTERPRETATION AND CONCLUSIONS CAD is associated with a decrease in fibrinolytic activity, possibly due to an increase in PAI-1 levels. An increase in fibrinolytic activity and a decrease in PAI-1 and Lp(a) levels were observed in CAD women receiving transdermal HRT and these changes may have a favorable impact on the risk of new cardiovascular events in post-menopausal CAD women.
Collapse
Affiliation(s)
- C Falcó
- Research Center, La Fe University Hospital, Valencia, Spain
| | | | | | | | | | | | | | | |
Collapse
|